Strength in science. Flexibility in partnership.
START YOUR JOURNEY
ChemPartner helps biotech and pharma teams advance from early discovery to IND-enabling development through connected chemistry, biology, pharmacology, DMPK, toxicology, and CMC support.
Years of Experience
clinic drugs advanced
IND programs supported
Drugs Reaching Market
One connected path from discovery to IND
Small Molecule
ChemPartner’s Small Molecule Discovery to IND pathway spans medicinal chemistry, assay development, hit identification, hit-to-lead optimization, lead optimization, DMPK, bioanalysis, exploratory toxicology, formulation development, CMC support, and IND-enabling activities.
Biologics
ChemPartner’s integrated platform for monoclonal, bispecific, and ADC/XDC programs combines protein science, stable cell line development, antibody discovery, engineering, structural biology, and conjugation support in one coordinated workflow — backed by 2,000+ scientists across a global network
Target ID & Validation
We confirm target relevance and druggability before chemistry begins, pairing disease biology and validation studies with AIDD-guided hypothesis testing.
Hit Identification
High-throughput and AIDD-guided virtual screening surface chemically tractable starting points, confirmed through primary and orthogonal biochemical assays and initial hit synthesis.
Drug Design
Medicinal chemistry, structure-based design, and iterative AIDD/CADD cycles turn early hits into prioritized, patentable series with the properties your program needs.
Hit to Lead
Focused SAR, synthetic chemistry, and in vitro pharmacology advance the most promising chemotypes, with early in vivo tolerability and PK studies confirming lead-quality series.
Lead Optimization
Iterative medicinal chemistry balances potency, selectivity, and PK/PD, refining leads against efficacy models until a molecule is ready for candidate nomination.
Candidate Selection & POC
ADME, PK/PD, exploratory toxicology, and in vivo proof-of-concept nominate a candidate, while early CMC feasibility confirms a developable path.
CMC & IND-enabling
Formulation, GLP toxicology, and scale-up for tox and clinical supply build an IND-ready package that moves your candidate into the clinic.
Target ID & Validation
Establishing the molecular foundation for your therapeutic antibody or biologic.
Hit Identification
Generating initial hits through advanced display and hybridoma technologies.
Drug Design
In silico engineering to optimize format and structural integrity.
Hit to Lead
Screening and selecting the most promising biologics for detailed characterization.
Lead Optimization
Refining the biologic to ensure clinical developability and maximal potency.
Candidate Selection & POC
Establishing manufacturability and early proof of therapeutic concept.
CMC & IND-enabling
Industrializing the biologic for clinical supply and IND success.
Scientific platforms that connect each decision
Discovery Chemistry & Molecular Design
Advance your program with integrated discovery chemistry and molecular design – from hit identification to optimized, development-ready candidates.
Characterization & Bioactivity
Build biological confidence with integrated characterization and bioactivity expertise that links structure and binding to real functional effect
Translational Pharmacology, DMPK & Toxicology
Generate decision-ready data with integrated translational pharmacology, DMPK, and toxicology expertise to advance candidates confidently toward the clinic.
CMC & Manufacturing Bridge
Bridge discovery and development with integrated CMC and manufacturing support that prepares your program for a seamless transition to the clinic.
Science that moves programs forward
Every engagement is a partnership, not a handoff. Explore how sponsors advance candidates across modalities and therapeutic areas.
Blog: Matching Preclinical Models to Late-Stage Disease
The Metastatic Challenge: Matching Preclinical Models to Late-Stage Disease In the first two posts of this 2026 series (syngeneic tumor
Blog: Beyond Subcutaneous Models
Beyond Subcutaneous Models: Rethinking Implantation Site in Preclinical Oncology In our first post of this series, we examined how tumor
Blog: Syngeneic Tumor Models
Syngeneic Tumor Models: The Gold Standard for Preclinical Immunotherapy Testing Cancer immunotherapy has transformed oncology, yet translating early efficacy into
A partnership built to move with your team
Whether you need a focused capability or an integrated path from discovery to IND, ChemPartner brings the platforms, infrastructure, and collaborative model to move with your team.